Pricing of oral generic cancer medicines in 25 European countries; findings and implications

被引：35

作者：

Godman, Brian ^{[1
,2
,3
,4
]}

Hill, Andrew ^{[5
]}

Simoens, Professor Steven ^{[6
]}

Kurdi, Amanj ^{[1
,7
]}

Gulbinovic, Jolanta ^{[8
]}

Martin, Antony P. ^{[2
,9
]}

Timoney, Angela ^{[1
,10
]}

Gotham, Dzintars

Wale, Janet ^{[11
]}

Bochenek, Tomasz ^{[12
]}

Rothe, Celia C. ^{[12
]}

Hoxha, Iris ^{[13
]}

Malaj, Admir ^{[14
]}

Hierlaender, Christian ^{[15
]}

Sauermann, Robert ^{[15
]}

Hamelinck, Wouter ^{[16
]}

Mitkova, Zornitsa ^{[17
]}

Petrova, Guenka ^{[17
]}

Laius, Ott ^{[18
]}

Sermet, Catherine ^{[19
]}

Langer, Irene ^{[20
]}

Selke, Gisbert W. ^{[20
]}

Yfantopoulos, John ^{[21
]}

Joppi, Roberta ^{[22
]}

Jakupi, Arianit ^{[23
]}

Poplavska, Elita ^{[24
,25
]}

Greiciute-Kuprijanov, Ieva ^{[26
]}

Bonanno, Patricia Vella ^{[1
]}

Piepenbrink, J. F. ^{[27
]}

de Valk, Vincent ^{[27
]}

Hagen, Carolin ^{[28
]}

Ringerud, Anne Marthe ^{[28
]}

Plisko, Robert ^{[29
]}

Wladysiuk, Magdalene ^{[29
]}

Markovic-Pekovic, Vanda ^{[30
,31
]}

Grubisa, Natasa ^{[32
]}

Ponorac, Tatjana ^{[33
]}

Mardare, Ileana ^{[34
]}

Novakovic, Tanja ^{[35
]}

Parker, Mark ^{[35
]}

Furst, Jurij ^{[36
]}

Tomek, Dominik ^{[37
]}

Cortadellas, Merce Obach ^{[38
]}

Zara, Corinne ^{[38
]}

Juhasz-Haverinen, Maria ^{[39
]}

Skiold, Peter ^{[40
]}

McTaggart, Stuart ^{[41
]}

Haycox, Alan ^{[1
]}

机构：

[1] Univ Strathclyde, Strathclyde Inst Pharm & Biomed Sci, Glasgow G4 0RE, Lanark, Scotland

[2] Univ Liverpool, Hlth Econ Ctr, Management Sch, Liverpool, Merseyside, England

[3] Karolinska Univ Hosp Huddinge, Karolinska Inst, Div Clin Pharmacol, SE-14186 Stockholm, Sweden

[4] Univ Sains Malaysia, Sch Pharmaceut Sci, George Town, Malaysia

[5] Univ Liverpool, Inst Translat Med, Liverpool, Merseyside, England

[6] Katholieke Univ Leuven, Dept Pharmaceut & Pharmacol Sci, Leuven, Belgium

[7] Hawler Med Univ, Coll Pharm, Dept Pharmacol, Erbil, Iraq

[8] Vilnius Univ, Fac Med, Inst Biomed Sci, Dept Pathol Forens Med & Pharmacol, Vilnius, Lithuania

[9] Innovat Ctr, HCD Econ, Daresbury WA4 4FS, England

[10] NHS Lothian, Edinburgh, Midlothian, Scotland

[11] 1 Lydia St, Brunswick, Vic 3056, Australia

[12] Jagiellonian Univ, Fac Hlth Sci, Dept Drug Management, Med Coll, Krakow, Poland

[13] Univ Med, Fac Med, Dept Pharm, Tirana, Albania

[14] Univ Med, Tirana, Albania

[15] Main Assoc Austrian Social Secur Inst, Dept Pharmaceut Affairs, 1 Haidingergasse, AT-1030 Vienna, Austria

[16] APB, Stat Dept, 11 Rue Archimede, BE-1000 Brussels, Belgium

[17] Med Univ Sofia, Dept Social Pharm & Pharmacoecon, Fac Pharm, Sofia, Bulgaria

[18] State Agcy Med, 1 Nooruse, EE-50411 Tartu, Estonia

[19] IRDES, 117 Bis Rue Manin, FR-75019 Paris, France

[20] Wissensch Inst AOK WidO, 31 Rosenthaler Str, DE-10178 Berlin, Germany

[21] Univ Athens, Sch Econ & Polit Sci, Athens, Greece

[22] Azienda Sanit Locale Verona, Pharmaceut Drug Dept, Verona, Italy

[23] UBT Higher Educ Inst Prishtina, Prishtina, Kosovo

[24] Riga Stradins Univ, Inst Publ Hlth, Riga, Latvia

[25] Riga Stradins Univ, Fac Pharm, Riga, Latvia

[26] Minist Hlth Republ Lithuania, Dept Pharm, Vilnius, Lithuania

[27] Natl Hlth Care Inst ZIN, 4 Eekholt, NL-1112 XH Diemen, Netherlands

[28] Norwegian Med Agcy, HTA & Reimbursement, Oslo, Norway

[29] HTA Consulting, 17-3 Starowislna Str, PL-31038 Krakow, Poland

[30] Minist Hlth & Social Welf, Banja Luka, Bosnia & Herceg

[31] Univ Banja Luka, Dept Social Pharm, Fac Med, Banja Luka, Republic Of Srp, Bosnia & Herceg

[32] Hlth Insurance Fund Republ Srpska, 8 Zdrave Korde, Banja Luka 78000, Republic Of Srp, Bosnia & Herceg

[33] Agcy Med & Med Devices Bosnia & Herzegovina, Veljka Mladjenovica Bb, Banja Luka 78000, Bosnia & Herceg

[34] Carol Davila Univ Med & Pharm Bucharest, Publ Hlth & Management Dept, Fac Med, RO-050463 Bucharest, Romania

[35] ZEM Solut, 9 Mosorska, RS-11000 Belgrade, Serbia

[36] Hlth Insurance Inst, 24 Miklasiceva, SI-1507 Ljubljana, Slovenia

[37] Slovak Med Univ Bratislava, Fac Med, Bratislava, Slovakia

[38] Catalan Hlth Serv, Barcelona Hlth Reg, Esteve Terrades 30, Barcelona 08023, Spain

[39] Stockholm Cty Council, Stockholm, Sweden

[40] TLV Dent & Pharmaceut Benefits Agcy, 18 Fleminggatan, SE-10422 Stockholm, Sweden

[41] NHS Natl Serv Scotland, Gyle Sq,1 South Gyle Crescent, Edinburgh EH12 9EB, Midlothian, Scotland

来源：

GABI JOURNAL-GENERICS AND BIOSIMILARS INITIATIVE JOURNAL | 2019年 / 8卷 / 02期

关键词：

Cancer; Europe; generic drug regulations; generics; health policy; pricing; ENHANCE PRESCRIBING EFFICIENCY; PROTON PUMP INHIBITORS; CARDIOVASCULAR-DISEASE; PATENT EXPIRY; LOW PRICES; DRUGS; POLICIES; COST; INITIATIVES; IMPACT;

D O I：

10.5639/gabij.2019.0802.007

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Introduction: There are appreciable concerns among European health authorities with growing expenditure on cancer medicines and issues of sustainability. The enhanced use of low-cost generics could help. Aims: Consequently, there is a need to comprehensively document current and future arrangements regarding the pricing of generic cancer medicines across Europe, and whether these are indication specific, as well as how this translates into actual prices to provide future direction. Methodology: Mixed-method approach with qualitative research among senior health authority personnel and their advisers. Quantitative research via health authority databases to ascertain current prices for oral cancer medicines that had lost their patent and the influence of population size and economics on prices. Results: Twenty-five European countries participated. The research found the following issues: (a) variable approaches to the pricing of generic cancer medicines, which will continue; (b) no concerns with substitution for oral generic cancer medicines; (c) substantial price reductions versus originators for generic capecitabine (up to -93.1%), generic imatinib (up to -97.8%) and generic temozolomide (up to -80.7%). Prices for oncology medicines are not generally indication specific, and are not affected by population size although influenced by pricing approaches. There have also been price increases for some non-patented cancer medicines following manufacturer changes although now stabilizing. Conclusion: The considerable price reductions seen for some generics means health authorities should further encourage the use of generic oncology medicines when they become available to fund increased volumes and new valued cancer medicines. Countries are also starting to address price increases for generics following changes in the manufacturer.

引用

页码：49 / 70

页数：22

共 116 条

[1]

Allied Market Research, ONC CANC DRUGS MARK

[2]

[Anonymous], 2008, HLTH POLICY B EUROPE

[3]

[Anonymous], CONVERSATION

[4]

[Anonymous], BMJ